Exploration of the drug regimen for the treatment of large cell neuroendocrine carcinoma of the cervix using a combination of Cardonizumab,chemotherapy,and Bevacizumab,with a case report attached
Cervical neuroendocrine carcinoma(NECC)is a kind of rare malignant tumors of the cervix,accounting for 1.4％of all cervical malignancies.Among NECCs,small cell neuroendocrine carcinoma is the most common,accounting for about 80％,followed by large cell neuroendocrine carcinoma accounting for about 12％,and other histological types such as undifferentiated neuroendocrine tumors account for about 8％.NECC is prone to early local spread and metastasis,with high malignancy and mortality rate,often resulting in poor prognosis.At present,a meta-analysis of 3538 cases of NECC shows that the most common initial treatment for NECC is radical surgery combined with chemotherapy,and there is no unified regimen for chemotherapy.There is also limited research on the use of cetuximab in the treatment of NECC.This article shares a case of endometrial adenocarcinoma that occurred 4 years after surgery.Due to"lower abdominal pain for more than 1 month",vaginal growths were found.After biopsy,the pathological diagnosis was large cell neuroendocrine carcinoma.Upon admission,the pelvic cavity showed a"frozen pelvis"and there was no surgical opportunity.Chemotherapy,targeted therapy,and immunotherapy were applied.After 4 courses of treatment,the effect was significant,so this article was published,hoping to provide new research directions for the subsequent treatment of NECC.
cervical large cell neuroendocrine carcinomaimmunotherapycardonimumab monoclonal antibody
万方数据
